Skip to main content
Erschienen in: Digestive Diseases and Sciences 3/2022

22.03.2021 | Original Article

Systematic Review with Meta-Analysis: Fecal Microbiota Transplantation for Severe or Fulminant Clostridioides difficile

verfasst von: Emily N. Tixier, Elijah Verheyen, Yuying Luo, Lauren Tal Grinspan, Charles H. Du, Ryan C. Ungaro, Samantha Walsh, Ari M. Grinspan

Erschienen in: Digestive Diseases and Sciences | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

Severe and fulminant Clostridioides difficile infection (CDI) is associated with significant morbidity and mortality. While fecal microbiota transplantation (FMT) has proved to be a highly effective treatment for recurrent CDI, its efficacy in severe or fulminant CDI remains uncertain.

Aims

To perform a systematic review with meta-analysis evaluating clinical outcomes and safety of FMT in severe and fulminant CDI.

Methods

A systemic review with meta-analysis was performed through comprehensive search of Embase, Medline (Ovid), trial registers, and conference abstracts through January 2020. Studies on FMT in severe and fulminant CDI were included. Meta-analysis was done with random effects models given heterogeneity to estimate rates of cure, mortality, and colectomy. Publication bias was assessed using Egger’s test.

Results

Sixteen studies comprised of one randomized controlled trial, four cohort studies, and eleven case series were analyzed. In total, 676 patients underwent FMT for severe or fulminant CDI. The overall rate of clinical cure after single FMT was 61.3% (95% CI 43.2–78.0%) with 10.9% (95% CI 0.2–30.2%) of patients experiencing major adverse events. The overall pooled colectomy rate after FMT was 8.2% (95% CI 0.1–23.7%) with a pooled all-cause mortality rate after FMT of 15.6% (95% CI 7.8–25.0%).

Conclusion

Low-quality data support the use of fecal microbiota transplantation in patients with severe and fulminant Clostridioides difficile infection.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Lessa FC, Winston LG, McDonald LC, Team EIPCdS. Burden of Clostridium difficile infection in the United States. N Engl J Med 2015;372:2369–2370PubMed Lessa FC, Winston LG, McDonald LC, Team EIPCdS. Burden of Clostridium difficile infection in the United States. N Engl J Med 2015;372:2369–2370PubMed
2.
Zurück zum Zitat Jaber MR, Olafsson S, Fung WL, Reeves ME. Clinical review of the management of fulminant Clostridium difficile infection. Am J Gastroenterol 2008;103:3195–3203PubMed Jaber MR, Olafsson S, Fung WL, Reeves ME. Clinical review of the management of fulminant Clostridium difficile infection. Am J Gastroenterol 2008;103:3195–3203PubMed
3.
Zurück zum Zitat Bhangu A, Nepogodiev D, Gupta A, Torrance A, Singh P. Systematic review and meta-analysis of outcomes following emergency surgery for Clostridium difficile colitis. Br J Surg 2012;99:1501–1513PubMed Bhangu A, Nepogodiev D, Gupta A, Torrance A, Singh P. Systematic review and meta-analysis of outcomes following emergency surgery for Clostridium difficile colitis. Br J Surg 2012;99:1501–1513PubMed
4.
Zurück zum Zitat McDonald LC, Gerding DN, Johnson S et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 2018;66:e1–48PubMedPubMedCentral McDonald LC, Gerding DN, Johnson S et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 2018;66:e1–48PubMedPubMedCentral
5.
Zurück zum Zitat Quraishi MN, Widlak M, Bhala N et al. Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection. Aliment Pharmacol Ther 2017;46:479–493PubMed Quraishi MN, Widlak M, Bhala N et al. Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection. Aliment Pharmacol Ther 2017;46:479–493PubMed
6.
Zurück zum Zitat Li YT, Cai HF, Wang ZH, Xu J, Fang JY. Systematic review with meta-analysis: long-term outcomes of faecal microbiota transplantation for Clostridium difficile infection. Aliment Pharmacol Ther 2016;43:445–457PubMed Li YT, Cai HF, Wang ZH, Xu J, Fang JY. Systematic review with meta-analysis: long-term outcomes of faecal microbiota transplantation for Clostridium difficile infection. Aliment Pharmacol Ther 2016;43:445–457PubMed
7.
Zurück zum Zitat Kassam Z, Lee CH, Yuan Y, Hunt RH. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol 2013;108:500–508PubMed Kassam Z, Lee CH, Yuan Y, Hunt RH. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol 2013;108:500–508PubMed
8.
Zurück zum Zitat Rokkas T, Gisbert JP, Gasbarrini A et al. A network meta-analysis of randomized controlled trials exploring the role of fecal microbiota transplantation in recurrent Clostridium difficile infection. United Eur Gastroenterol J 2019;7:1051–1063 Rokkas T, Gisbert JP, Gasbarrini A et al. A network meta-analysis of randomized controlled trials exploring the role of fecal microbiota transplantation in recurrent Clostridium difficile infection. United Eur Gastroenterol J 2019;7:1051–1063
9.
Zurück zum Zitat van Beurden YH, Nieuwdorp M, van de Berg P, Mulder CJJ, Goorhuis A. Current challenges in the treatment of severe Clostridium difficile infection: early treatment potential of fecal microbiota transplantation. Ther Adv Gastroenterol 2017;10:373–381 van Beurden YH, Nieuwdorp M, van de Berg P, Mulder CJJ, Goorhuis A. Current challenges in the treatment of severe Clostridium difficile infection: early treatment potential of fecal microbiota transplantation. Ther Adv Gastroenterol 2017;10:373–381
10.
Zurück zum Zitat Moher D, Liberati A, Tetzlaff J, Altman DG, the PG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151:264–269PubMed Moher D, Liberati A, Tetzlaff J, Altman DG, the PG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151:264–269PubMed
11.
Zurück zum Zitat Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 1994;47:1245–1251PubMed Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 1994;47:1245–1251PubMed
12.
Zurück zum Zitat Higgins JP, Altman DG, Gotzsche PC et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928PubMedPubMedCentral Higgins JP, Altman DG, Gotzsche PC et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928PubMedPubMedCentral
14.
Zurück zum Zitat Owens DK, Lohr KN, Atkins D et al. AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions—agency for healthcare research and quality and the effective health-care program. J Clin Epidemiol 2010;63:513–523PubMed Owens DK, Lohr KN, Atkins D et al. AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions—agency for healthcare research and quality and the effective health-care program. J Clin Epidemiol 2010;63:513–523PubMed
15.
Zurück zum Zitat Freeman MF, Tukey JW. Transformations related to the angular and the square root. Ann Math Stat 1950;21:607–611 Freeman MF, Tukey JW. Transformations related to the angular and the square root. Ann Math Stat 1950;21:607–611
16.
Zurück zum Zitat Schwarzer G, Carpenter JR, Rücker G. Meta-analysis with R, New York: Springer; 2015; 61–62 Schwarzer G, Carpenter JR, Rücker G. Meta-analysis with R, New York: Springer; 2015; 61–62
17.
Zurück zum Zitat Ianiro G, Masucci L, Quaranta G et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy plus vancomycin for the treatment of severe refractory Clostridium difficile infection-single versus multiple infusions. Aliment Pharmacol Ther 2018;48:152–159PubMed Ianiro G, Masucci L, Quaranta G et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy plus vancomycin for the treatment of severe refractory Clostridium difficile infection-single versus multiple infusions. Aliment Pharmacol Ther 2018;48:152–159PubMed
18.
Zurück zum Zitat Cheng YW, Phelps E, Nemes S et al. Fecal microbiota transplant decreases mortality in patients with refractory severe or fulminant Clostridioides difficile infection. Clin Gastroenterol Hepatol 2020;18:2234–2243PubMed Cheng YW, Phelps E, Nemes S et al. Fecal microbiota transplant decreases mortality in patients with refractory severe or fulminant Clostridioides difficile infection. Clin Gastroenterol Hepatol 2020;18:2234–2243PubMed
19.
Zurück zum Zitat Mallick R, Vakayil V, Lord A et al. Therapeutic strategies for severe and severe-complicated Clostridium difficile infection. Gastroenterology 2017;152:S1304 Mallick R, Vakayil V, Lord A et al. Therapeutic strategies for severe and severe-complicated Clostridium difficile infection. Gastroenterology 2017;152:S1304
21.
Zurück zum Zitat Agrawal M, Aroniadis OC, Brandt LJ et al. The long-term efficacy and safety of fecal microbiota transplant for recurrent, severe, and complicated Clostridium difficile infection in 146 elderly individuals. J Clin Gastroenterol 2016;50:403–407PubMed Agrawal M, Aroniadis OC, Brandt LJ et al. The long-term efficacy and safety of fecal microbiota transplant for recurrent, severe, and complicated Clostridium difficile infection in 146 elderly individuals. J Clin Gastroenterol 2016;50:403–407PubMed
22.
Zurück zum Zitat Tixier E, Verheyen E, Ungaro R, Grinspan A. Faecal microbiota transplant decreases mortality in severe and fulminant Clostridioides difficile infection in critically ill patients. Aliment Pharmacol Ther 2019;50:1094–1099PubMedPubMedCentral Tixier E, Verheyen E, Ungaro R, Grinspan A. Faecal microbiota transplant decreases mortality in severe and fulminant Clostridioides difficile infection in critically ill patients. Aliment Pharmacol Ther 2019;50:1094–1099PubMedPubMedCentral
23.
Zurück zum Zitat Duarte-Chavez R, Wojda TR, Zanders TB, Geme B, Fioravanti G, Stawicki SP. Early results of fecal microbial transplantation protocol implementation at a community-based university hospital. J Glob Infect Dis 2018;10:47–57PubMedPubMedCentral Duarte-Chavez R, Wojda TR, Zanders TB, Geme B, Fioravanti G, Stawicki SP. Early results of fecal microbial transplantation protocol implementation at a community-based university hospital. J Glob Infect Dis 2018;10:47–57PubMedPubMedCentral
24.
Zurück zum Zitat Hocquart M, Lagier J-C, Cassir N et al. Early fecal microbiota transplantation improves survival in severe Clostridium difficile infections. Clin Infect Dis 2018;66:645–650PubMed Hocquart M, Lagier J-C, Cassir N et al. Early fecal microbiota transplantation improves survival in severe Clostridium difficile infections. Clin Infect Dis 2018;66:645–650PubMed
25.
Zurück zum Zitat Greenberg SA, Youngster I, Cohen NA et al. Five years of fecal microbiota transplantation—an update of the Israeli experience. World J Gastroenterol 2018;24:5403–5414PubMedPubMedCentral Greenberg SA, Youngster I, Cohen NA et al. Five years of fecal microbiota transplantation—an update of the Israeli experience. World J Gastroenterol 2018;24:5403–5414PubMedPubMedCentral
26.
Zurück zum Zitat Ianiro G, Valerio L, Masucci L et al. Predictors of failure after single faecal microbiota transplantation in patients with recurrent Clostridium difficile infection: results from a 3-year, single-centre cohort study. Clin Microbiol Infect 2017;23:337.e331-337.e333 Ianiro G, Valerio L, Masucci L et al. Predictors of failure after single faecal microbiota transplantation in patients with recurrent Clostridium difficile infection: results from a 3-year, single-centre cohort study. Clin Microbiol Infect 2017;23:337.e331-337.e333
27.
Zurück zum Zitat Rokas KE, Johnson JW, Beardsley JR, Ohl CA, Luther VP, Williamson JC. The addition of intravenous metronidazole to oral vancomycin is associated with improved mortality in critically ill patients with Clostridium difficile infection. Clin Infect Dis 2015;61:934–941PubMed Rokas KE, Johnson JW, Beardsley JR, Ohl CA, Luther VP, Williamson JC. The addition of intravenous metronidazole to oral vancomycin is associated with improved mortality in critically ill patients with Clostridium difficile infection. Clin Infect Dis 2015;61:934–941PubMed
28.
Zurück zum Zitat Cornely OA, Nathwani D, Ivanescu C, Odufowora-Sita O, Retsa P, Odeyemi IA. Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison. J Antimicrob Chemother 2014;69:2892–2900PubMed Cornely OA, Nathwani D, Ivanescu C, Odufowora-Sita O, Retsa P, Odeyemi IA. Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison. J Antimicrob Chemother 2014;69:2892–2900PubMed
29.
Zurück zum Zitat Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007;45:302–307PubMed Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007;45:302–307PubMed
30.
Zurück zum Zitat Louie TJ, Miller MA, Mullane KM et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011;364:422–431PubMed Louie TJ, Miller MA, Mullane KM et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011;364:422–431PubMed
31.
Zurück zum Zitat Housman ST, Thabit AK, Kuti JL, Quintiliani R, Nicolau DP. Assessment of Clostridium difficile burden in patients over time with first episode infection following fidaxomicin or vancomycin. Infect Control Hosp Epidemiol 2016;37:215–218PubMed Housman ST, Thabit AK, Kuti JL, Quintiliani R, Nicolau DP. Assessment of Clostridium difficile burden in patients over time with first episode infection following fidaxomicin or vancomycin. Infect Control Hosp Epidemiol 2016;37:215–218PubMed
32.
Zurück zum Zitat Dallas KB, Condren A, Divino CM. Life after colectomy for fulminant Clostridium difficile colitis: a 7-year follow up study. Am J Surg 2014;207:533–539PubMed Dallas KB, Condren A, Divino CM. Life after colectomy for fulminant Clostridium difficile colitis: a 7-year follow up study. Am J Surg 2014;207:533–539PubMed
33.
Zurück zum Zitat Byrn J, Maun DC, Gingold DS, Baril DT, Ozao JJ, Divino CM. Predictors of mortality after colectomy for fulminant Clostridium difficile colitis. Arch Surg 2008;143:150–154PubMed Byrn J, Maun DC, Gingold DS, Baril DT, Ozao JJ, Divino CM. Predictors of mortality after colectomy for fulminant Clostridium difficile colitis. Arch Surg 2008;143:150–154PubMed
34.
Zurück zum Zitat Neal MD, Alverdy JC, Hall DE, Simmons RL, Zuckerbraun BS. Diverting loop ileostomy and colonic lavage: an alternative to total abdominal colectomy for the treatment of severe, complicated Clostridium difficile associated disease. Ann Surg 2011;254:423–427PubMed Neal MD, Alverdy JC, Hall DE, Simmons RL, Zuckerbraun BS. Diverting loop ileostomy and colonic lavage: an alternative to total abdominal colectomy for the treatment of severe, complicated Clostridium difficile associated disease. Ann Surg 2011;254:423–427PubMed
35.
Zurück zum Zitat Juo YY, Sanaiha Y, Jabaji Z, Benharash P. Trends in diverting loop ileostomy vs total abdominal colectomy as surgical management for Clostridium difficile colitis. JAMA Surg 2019;154:899–906PubMedPubMedCentral Juo YY, Sanaiha Y, Jabaji Z, Benharash P. Trends in diverting loop ileostomy vs total abdominal colectomy as surgical management for Clostridium difficile colitis. JAMA Surg 2019;154:899–906PubMedPubMedCentral
36.
Zurück zum Zitat Hall BR, Leinicke JA, Armijo PR, Smith LM, Langenfeld SJ, Oleynikov D. No survival advantage exists for patients undergoing loop ileostomy for Clostridium difficile colitis. Am J Surg 2019;217:34–39PubMed Hall BR, Leinicke JA, Armijo PR, Smith LM, Langenfeld SJ, Oleynikov D. No survival advantage exists for patients undergoing loop ileostomy for Clostridium difficile colitis. Am J Surg 2019;217:34–39PubMed
37.
Zurück zum Zitat Sailhamer EA, Carson K, Chang Y et al. Fulminant Clostridium difficile colitis: patterns of care and predictors of mortality. Arch Surg 2009;144:433–439PubMed Sailhamer EA, Carson K, Chang Y et al. Fulminant Clostridium difficile colitis: patterns of care and predictors of mortality. Arch Surg 2009;144:433–439PubMed
38.
Zurück zum Zitat Cammarota G, Ianiro G, Magalini S, Gasbarrini A, Gui D. Decrease in surgery for Clostridium difficile infection after starting a program to transplant fecal microbiota. Ann Intern Med 2015;163:487–488PubMed Cammarota G, Ianiro G, Magalini S, Gasbarrini A, Gui D. Decrease in surgery for Clostridium difficile infection after starting a program to transplant fecal microbiota. Ann Intern Med 2015;163:487–488PubMed
39.
Zurück zum Zitat Kulaylat AS, Hollenbeak CS, Stewart DB. A surgical clostridium-associated risk of death score predicts mortality after colectomy for Clostridium difficile. Dis Colon Rectum 2017;60:1285–1290PubMed Kulaylat AS, Hollenbeak CS, Stewart DB. A surgical clostridium-associated risk of death score predicts mortality after colectomy for Clostridium difficile. Dis Colon Rectum 2017;60:1285–1290PubMed
40.
Zurück zum Zitat Bishop E, Tiruvoipati R, Metcalfe J, Marshall C, Botha J, Kelley PG. The outcome of patients with severe and severe-complicated Clostridium difficile infection treated with tigecycline combination therapy: a retrospective observational study. Intern Med J 2018;48:651–660PubMed Bishop E, Tiruvoipati R, Metcalfe J, Marshall C, Botha J, Kelley PG. The outcome of patients with severe and severe-complicated Clostridium difficile infection treated with tigecycline combination therapy: a retrospective observational study. Intern Med J 2018;48:651–660PubMed
42.
Zurück zum Zitat DeFilipp Z, Bloom P, Torres- Soto M et al. Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant. N Engl J Med 2019;381:2043–2050PubMed DeFilipp Z, Bloom P, Torres- Soto M et al. Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant. N Engl J Med 2019;381:2043–2050PubMed
43.
Zurück zum Zitat Fischer M, Sipe B, Cheng Y-W et al. Fecal microbiota transplant in severe and severe-complicated Clostridium difficile: a promising treatment approach. Gut Microbes 2017;8:289–302PubMed Fischer M, Sipe B, Cheng Y-W et al. Fecal microbiota transplant in severe and severe-complicated Clostridium difficile: a promising treatment approach. Gut Microbes 2017;8:289–302PubMed
44.
Zurück zum Zitat Bhatt DL, Mehta C. Adaptive designs for clinical trials. N Engl J Med 2016;375:65–74PubMed Bhatt DL, Mehta C. Adaptive designs for clinical trials. N Engl J Med 2016;375:65–74PubMed
45.
Zurück zum Zitat Aroniadis OF, Brandt LJ, Greenberg A et al. Long-term follow-up study of fecal microbiota transplantation for severe and/or complicated Clostridium difficile infection: a multicenter experience. J Clin Gastroenterol 2016;50:398–402PubMed Aroniadis OF, Brandt LJ, Greenberg A et al. Long-term follow-up study of fecal microbiota transplantation for severe and/or complicated Clostridium difficile infection: a multicenter experience. J Clin Gastroenterol 2016;50:398–402PubMed
46.
Zurück zum Zitat Dimitry J, Keshteli AH, Kao D. Predictors of failure of fecal microbiota transplantation (FMT) in the management of recurrent Clostridium difficile infection. Gastroenterology. 2016;150:S543 Dimitry J, Keshteli AH, Kao D. Predictors of failure of fecal microbiota transplantation (FMT) in the management of recurrent Clostridium difficile infection. Gastroenterology. 2016;150:S543
47.
Zurück zum Zitat Gachette DBM, Rupawala AH, Jimoh L, Kelly CR. Inpatient management of severe clostridium infection using fecal microbiota transplant via retention enema. Gastroenterology 2019;156:S902 Gachette DBM, Rupawala AH, Jimoh L, Kelly CR. Inpatient management of severe clostridium infection using fecal microbiota transplant via retention enema. Gastroenterology 2019;156:S902
48.
Zurück zum Zitat O’Brien K, Osman M, Eysenbach L et al. Clinical efficacy of fecal microbiota transplantation for recurrent Clostridium difficile infection from an international public stool bank: results from a 1,406 patient multi-center cohort. Gastroenterology 2016;150:S539-540 O’Brien K, Osman M, Eysenbach L et al. Clinical efficacy of fecal microbiota transplantation for recurrent Clostridium difficile infection from an international public stool bank: results from a 1,406 patient multi-center cohort. Gastroenterology 2016;150:S539-540
49.
Zurück zum Zitat Tiwari A, Sharma H, Qamar K et al. Sa1844—factors predicting relapse of Clostridium difficle colitis following fecal microbiota transplantation (FMT). Gastroenterology 2018;154:S416 Tiwari A, Sharma H, Qamar K et al. Sa1844—factors predicting relapse of Clostridium difficle colitis following fecal microbiota transplantation (FMT). Gastroenterology 2018;154:S416
50.
Zurück zum Zitat Tucker ETK, Gill M, Bryant R, Costello S. Fecal microbiota transplantation using a centralized frozen stool bank is effective and safe for the treatment of severe Clostridioides difficile infection. J Gastroenterol Hepatol 2019;34:S177 Tucker ETK, Gill M, Bryant R, Costello S. Fecal microbiota transplantation using a centralized frozen stool bank is effective and safe for the treatment of severe Clostridioides difficile infection. J Gastroenterol Hepatol 2019;34:S177
Metadaten
Titel
Systematic Review with Meta-Analysis: Fecal Microbiota Transplantation for Severe or Fulminant Clostridioides difficile
verfasst von
Emily N. Tixier
Elijah Verheyen
Yuying Luo
Lauren Tal Grinspan
Charles H. Du
Ryan C. Ungaro
Samantha Walsh
Ari M. Grinspan
Publikationsdatum
22.03.2021
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 3/2022
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-021-06908-4

Weitere Artikel der Ausgabe 3/2022

Digestive Diseases and Sciences 3/2022 Zur Ausgabe

DDS Author Profiles

Author Spotlight: Wendy Zhou

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.